Jessica Nye, PhD February 8, 2023
Study authors did not identify clear pain-relieving effects from CBD and/or THC among patients with peripheral neuropathic pain and prior treatment failure.
Oral cannabidiol (CBD), tetrahydrocannabinol (THC), or their combination did not decrease pain among patients with peripheral neuropathic pain who had a history of treatment failure. These findings, from a randomized, double-blind trial, were published in the European Journal of Pain.
The median age of the study population was 65 (range, 22-95) years, the median duration of pain was 60 (range, 10-2017) months, mean NRS score was 6.5 (standard deviation [SD], 1.3) points, and the most common prior therapy was gabapentin or pregabalin (n=115). Neuropathic etiologies included polyneuropathy (n=95), diabetic polyneuropathy
“In the PPP, CBD reduced pain less than placebo, and less effect of CBD than of placebo was also seen with some secondary pain outcomes.”
Neither CBD, THC, nor CBD/THC were superior to placebo for symptoms of burning pain, pressing and squeezing, pain paroxysms, or evoked pain as evaluated using the Neuropathic Pain Symptom Inventory (NPSI). The study authors report that CBD was actually less effective than placebo in reducing evoked pain.
No effects on paracetamol consumption, quality of life, or psychomotor function were reported with active treatment.
In subgroup analyses, active treatment was not superior to placebo for pain, quality of life, mood, or pain-related sleep disturbance.
Nausea and diarrhea were reported more frequently among recipients of CBD/THC compared with prior to treatment (11% vs 1% and 11% vs 3%, respectively).
Featured Website
World Federation Against Drugs
World Federation Against Drugs (W.F.A.D) Dalgarno Institute is a member of this global initiative. For evidence based data on best practice drug policy in the global context.
Featured Website
Institute for Behavior and Health
The Institute for Behavior and Health, Inc. is to reduce the use of illegal drugs. We work to achieve this mission by conducting research, promoting ideas that are affordable and scalable...
Featured Website
Drug Free Australia
Drug Free Australia Website. Drug Free Australia is a peak body, representing organizations and individuals who value the health and wellbeing of our nation...
Featured Website
Drug Advisory Council of Australia (D.A.C.A)
Drug Advisory Council of Australia (D.A.C.A) Dalgarno Institute is an executive member of this peak body. For updates on current illicit drug issues.
Featured Website
International Task Force on Strategic Drug Policy
(I.T.F.S.D.P) This international peak body continues to monitor and influence illicit drug policy on the international stage. Dalgarno Institute is a member organisation.
Featured Website
Smart Approaches to Marijuana
Smart Approaches to Marijuana. SAM's leaders are among the world's most prominent voices calling for science-based marijuana education and awareness.
21 Be There
There isn’t merely data sharing - it isn't about promoting a 'one dimensional' legislative solution to a complex problem
Featured Website
Drug Free Futures
Drug Policy Futures believes in engaging in an open dialogue about the strengths and weaknesses of global drug policies...
Featured Website
Action Alcohol
The National Alliance for Action on Alcohol is a national coalition of health and community organisations from across Australia that has been formed with the goal of reducing alcohol-related harm.
Featured Website
Rivermend Health
RiverMend Health is a premier provider of scientifically driven, specialty behavioral health services to those suffering from alcohol and drug dependency, dual disorders, eating disorders, obesity and chronic pain.
Featured Website
Evidence-Based Practices Resource Center
SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.
Featured Website
SAMHSA
SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.